BOJI CRO: "FCZR" has received the drug clinical trial approval notice
BOJI CRO recently announced that its application for "FCZR" has received the clinical trial approval notice from the National Medical Products Administration. FCZR is a modified new drug targeting ear fungal disease, with significant clinical advantages. The drug's formulation and administration method have been optimized for ear drop application, allowing it to directly act on the ear canal lesions. Currently, there are no similar drugs approved for marketing domestically or internationally
According to the Zhitong Finance APP, BOJI CRO (300404.SZ) announced that the "FCZR" it applied for has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration.
FCZR is a 2.2/2.4 class modified new drug optimized based on known active ingredients, with improvements in dosage form, prescription process, administration route, and indications, and has significant clinical advantages. The proposed indication is for ear fungal disease. Ear fungal disease is a common infectious disease in otolaryngology outpatient clinics, often occurring in hot and humid seasons and regions, frequently recurring and difficult to cure. The dosage form of FCZR has advantages in fluidity and ease of administration, allowing ear drops to directly contact lesions in various hidden corners of the ear canal, achieving local effect through local administration. Currently, there are no such drugs approved for marketing domestically or internationally, nor are there any related sales data
